
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
ROSE-Longitudinal Assessment With Neuroimaging
State University of New York at Buffalo
Intracerebral Hemorrhage
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE
study of cases with deep and lobar intracerebral hemorrhage to perform advanced
neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function
at baseline, 6 months after baseline, and 121 expand
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date. Type: Observational Start Date: Sep 2020 |
|
CT TAVR Abdomen Study
University of Maryland, Baltimore
Transcatheter Aortic Valve Replacement
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated
contrast. A recent world-wide shortage of iodine based intravenous contrast has
highlighted the need to search for alternative methods or doses. Reducing iodinated IV
contrast dose can mitigate IV contrast supp1 expand
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure. Type: Interventional Start Date: Sep 2023 |
|
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Dennis M. McNamara, MD, MS
Peripartum Cardiomyopathy, Postpartum
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5
months postpartum in a randomized placebo controlled trial of bromocriptine therapy to
evaluate its impact on myocardial recovery and clinical outcomes. Given that
bromocriptine prevents breastfeeding, an additi1 expand
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort. Type: Interventional Start Date: Jul 2022 |
|
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Temple University
COPD
Parallel-group, prospective, randomized, controlled phase III trial of home High flow
Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical
care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients
with moderate to very severe COPD at1 expand
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks. Type: Interventional Start Date: Feb 2022 |